Sep 2026· The American Journal of Chinese Medicine· Vol 54, pp.
1-30
· 0 citations· 97 references
Medicine
TL;DR
The results indicate that gut microbiota dysbiosis drives IBS symptoms through three major metabolic pathways - short-chain fatty acids, bile acids, and 5-hydroxytryptamine - and achieves bidirectional regulation via the GBA.
Abstract
Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, with dysfunction of the gut-brain axis (GBA) being its core pathogenic mechanism. Traditional Chinese Medicine (TCM), guided by the theory of "liver-spleen interaction" and the core therapeutic principle of "soothing the liver and invigorating the spleen", has accumulated extensive clinical experience in IBS treatment. This review systematically searched PubMed, Web of Science, and CNKI databases to summarize the molecular mechanisms by which gut microbiota participate in IBS pathogenesis through the GBA, interpret the modern biological connotation of the TCM pathogenesis of "liver depression and spleen deficiency" from the perspective of the GBA, and review the evidence for TCM in treating IBS by modulating gut microbiota. The results indicate that gut microbiota dysbiosis drives IBS symptoms through three major metabolic pathways - short-chain fatty acids, bile acids, and 5-hydroxytryptamine - and achieves bidirectional regulation via the GBA. TCM monomers (e.g., berberine, curcumin, apigenin), single herbs (e.g., Atractylodes, Cinnamomum, Liupao tea), classical formulas (e.g., Tong-Xie-Yao-Fang, Chang-Kang-Fang, Si-Ni-San), as well as acupuncture and moxibustion, may improve IBS symptoms by restoring gut microbial diversity, regulating metabolite levels, repairing the intestinal barrier, and inhibiting inflammatory pathways. TCM may offer unique advantages in treating IBS through multi-target regulation of gut microbiota. Future research should focus on the objectification of TCM syndrome differentiation based on gut microbiota and the development of precision matching strategies.
The authors analyze GBA dysfunction across major DGBIs subtypes (irritable bowel syndrome, functional dyspepsia, and functional abdominal pain syndrome), highlighting microbiota dysbiosis, barrier dysfunction, and central sensitization.
Cong Yu, Xiu-Juan Wang, Shu-Zhu Chen· The Turkish Journal of Gastr...· 1 citation
Abstract Background The gut microbiota plays a significant role in maintaining host homeostasis by influencing metabolism, immune system function, and bidirectional communication within the gut–brain axis. Numerous studies have demonstrated a correlation between alterations in microbial composition and activity, and th...
Monika Ziemba, Katarzyna Majewska, Paulina Orzechowska et al.· Biuletyn Głównej Biblioteki...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disorder worldwide, characterized by a multifactorial pathogenesis involving genetic predisposition, metabolic disturbances, environmental influences, and gut microbiota interactions. In recent years, the gu...
Wen-Xing Liu, Y.-Q. Lan, Xia Chen et al.· Frontiers in Microbiology· 0 citations
This paper provides a comprehensive review of the current state of knowledge on irritable bowel syndrome (IBS), one of the most common gastrointestinal disorders, currently classified as a disorder of gut–brain interaction (DGBI). The review discusses the epidemiology, pathophysiology, clinical presentation, diagnostic...
Marlena Radzka, Izabela Radzka, Paweł Budzik et al.· International Journal of Inn...· 0 citations
TCM represents a promising microbiota-targeted strategy for mitigating chemotherapy-induced toxicities in gastric cancer through gut microbiota regulation, and future studies should focus on STING signaling and the gut–brain axis to advance evidence-based integrative oncology.
Jia-Lin Li, Fa-Xiang Ji· Supportive Care in Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.